Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...

Hims & Hers Health has called time on Apostrophe, its personalised acne treatments business. The San Francisco-based ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared "aspirational." ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The message suggested visiting Hims & Hers to pursue further skincare treatment. "After careful consideration, we are discontinuing Apostrophe to simplify our dermatology products and operations ...